Biological E. Receives Phase II WHO Pre-Qualification for nOPV2

▴ Pre-Qualification for nOPV2
Integrated WHO-qualified manufacturing strengthens supply availability for cVDPV2 outbreak control.

Hyderabad, February 12, 2026: Biological E. Limited (BE) today announced a major milestone in the global fight against polio, with the World Health Organization (WHO) granting Phase II Pre-Qualification (PQ) for its Novel Oral Polio Vaccine type 2 (nOPV2).

Phase II Pre-Qualification covers both Drug Substance and Drug Product manufactured at BE, completing the full manufacturing chain for nOPV2 at a single integrated site. This expands BE’s WHO-qualified manufacturing scope beyond Phase I, under which the company received PQ in June 2024 for drug product manufacturing using externally supplied drug substance.  BE has already manufactured and supplied 700 million doses of nOPV2 to the product stockpile and shipped to multiple countries where nOPV2 immunization campaigns are underway to control circulating vaccine-derived poliovirus type 2 (cVDPV2 ) outbreaks. 

The expanded qualification significantly strengthens global outbreak response readiness by adding integrated, WHO-qualified production capacity for nOPV2 — a critical vaccine used in controlling cVDPV2 outbreaks. The achievement reflects a multi-year, multi-partner global collaboration involving technology transfer, product comparability assessment, specialized testing, and manufacturing readiness programs across institutions. This milestone powerfully demonstrates India’s ability to deliver life-saving vaccines at scale, supporting rapid, reliable supply for global polio elimination efforts and protecting children worldwide.

Commenting on the milestone, Mahima Datla, Managing Director, Biological E. Limited, said “When polio outbreaks occur, response time and vaccine availability determine how quickly transmission can be stopped. nOPV2 has already been deployed in over a billion doses globally because it is designed specifically for outbreak control with improved genetic stability.”

“With Phase II WHO Pre-Qualification enabling full end-to-end manufacturing at our facilities, global supply becomes more resilient and more responsive. That matters because every delay in outbreak response carries real risk for children and communities.”

“This progress reflects the critical contributions of PT Bio Farma (Indonesia), PATH, and the Gates Foundation in technical and programmatic support.”

With integrated manufacturing infrastructure, validated processes, and export regulatory approvals already in place, BE is well positioned to support global program requirements as demand evolves. The Phase II qualification further enhances BE’s ability to ensure continuous, flexible, and rapid vaccine supply for international outbreak control programs, highlighting India’s leadership in delivering innovative, high-impact solutions that enable global polio eradication.”

 

Tags : #

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026